Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Completes Warrant Conversion, Allots 44,000 Equity Shares
FUNDRAISE
▲ Positive Development
LOW RISK
📅 Filed on BSE: 23 Oct 2026, 06:26 PM IST · BSE ID: 76e95797-e2ee-4dc2-bead-5c5813f03edd
View Original BSE Filing (PDF)
💡
In Simple Terms
The company issued new shares to investors who previously held warrants, after adjusting for a recent bonus share distribution.
🤖 AI Summary
- Fredun Pharmaceuticals allotted 44,000 equity shares to non-promoter investors.
- Allotment follows conversion of 14,667 warrants into equity shares.
- Warrants adjusted for a 1:2 bonus issue ratio impacting share count.
- Three non-promoter investors, including Divya Aggarwal, received shares.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Number of Equity Shares allotted
44,000
Number of Convertible Warrants converted
14,667
Number of Non-Promoter Investors
3
Face value per Equity Share
Rs. 10/-
Total number of convertible warrants allotted on December 29, 2025
20,000
🏢 How This Affects the Company
The conversion of warrants into equity shares increases the company's issued share capital and extinguishes outstanding warrants. This also implies the receipt of the balance consideration for the warrants.
The conversion reduces the number of outstanding warrants, removing a potential future dilution event linked to these specific warrants.
👥 What This Means For Shareholders
✅
Action Required
No action is required from existing shareholders regarding this allotment.
👤
Who Is Affected
The 44,000 equity shares are allotted to three specific non-promoter investors: Divya Aggarwal, Indu Ramanlal Golecha, and Sahil Dhir.
🔍
Management Signal
This action confirms management's commitment to completing prior capital raising instruments as per terms.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Next quarterly results disclosure for updated shareholding patterns.
Any future capital raising announcements by the company.
Management commentary on financial performance in upcoming investor calls.
LOW RISK
Routine completion of prior financial instrument conversion with no new risks introduced.
💡 Investor Takeaway
Fredun Pharmaceuticals allotted 44,000 equity shares to three non-promoter investors upon conversion of 14,667 warrants, following a 1:2 bonus issue adjustment. All warrants from the December 29, 2025, allotment are now exercised.
⚖️ Strengths & Concerns
✅ Positives
- Successful conversion of 14,667 warrants into 44,000 equity shares by non-promoter investors.
- All warrants originally allotted on December 29, 2025, are now converted, with zero warrants outstanding.
📅 Company Track Record
Previous filings show promoter warrant conversions in April 2026 and March 2026, totaling over 146,000 equity shares and Rs. 13.75 Crore invested.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
How many equity shares did Fredun Pharmaceuticals allot from warrant conversion?
Fredun Pharmaceuticals allotted 44,000 equity shares upon conversion of 14,667 warrants.
Who are the allottees of the new equity shares?
The 44,000 equity shares were allotted to three non-promoter investors: Divya Aggarwal, Indu Ramanlal Golecha, and Sahil Dhir.
Were the warrants adjusted for the bonus issue?
Yes, the warrants were adjusted for the company's 1:2 bonus issue, impacting the number of shares issued per warrant.
How many warrants were initially allotted on December 29, 2025?
A total of 20,000 convertible warrants were initially allotted on December 29, 2025, to these three investors.
Are there any warrants outstanding after this allotment?
No, following this allotment, there are zero warrants outstanding from the December 29, 2025, issuance.
Questions based on this BSE filing only. For information purposes.